(Q35871855)

10 August 2017

1 reference

title

Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis (English)

1 reference

10 August 2017

1 reference

Sonja Merkesdal

1

1 reference

10 August 2017

Jörg Ruof

series ordinal

2

1 reference

10 August 2017

Thomas Mittendorf

series ordinal

3

1 reference

10 August 2017

Henning Zeidler

series ordinal

4

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Expert Opinion on Pharmacotherapy

10 August 2017

published in

1 reference

10 August 2017

volume

5

1 reference

10 August 2017

issue

9

1 reference

10 August 2017

page(s)

1881-1886

1 reference

Health economics research in the area of chronic polyarthritis

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1881

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1881

A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1881

Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1881

TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1881

A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1881

The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.9.1881

10.1517/14656566.5.9.1881

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference